Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902928 | 0.89 | TSHR (0.36) | MAOBMAOAMEN1CYP1A2CYP2C9 | |
| SCHEMBL4892334 | 0.85 | ALDH1A1 (0.34) | MAOBMAOANOS2ALDH1A1 | |
| SCHEMBL4875980 | 0.83 | TSHR (0.33) | — | |
| SCHEMBL4901053 | 0.82 | TSHR (0.37) | MAOBMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4898932 | 0.75 | VCP (0.36) | MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL4903034 | 0.74 | NOS2 (0.36) | MAOBMAOAMEN1CYP2C9CYP2C19 | |
| SCHEMBL4894124 | 0.73 | L3MBTL1 (0.33) | MAOBMAOAMEN1KMT2AL3MBTL1 | |
| SCHEMBL4884251 | 0.72 | ALDH1A1 (0.31) | MAOBALDH1A1 | |
| SCHEMBL4900769 | 0.71 | MAOB (0.35) | MAOBMEN1KMT2AL3MBTL1TACR1 | |
| SCHEMBL14154011 | 0.71 | TSHR (0.33) | MAOBMAOANOS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | PFIZER INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1740550-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005100322-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | PFIZER LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132549-A1 | Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids | SPR, TPMT, IMPDH1 | MAOB 1130/4885MAOA 2292/4885MEN1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.